Trump signs order to speed psychedelic research and expand patient access

President Donald Trump signed an executive order on April 17 directing U.S. agencies to accelerate research and expand clinical access to psychedelics^[1].

The move arrives as the nation grapples with a mental‑health crisis that has left millions without effective treatment options. Proponents argue that psychedelics could offer new pathways for conditions such as depression, PTSD, and addiction, and the order could shift federal resources toward those possibilities^[1][2].

The order tasks the National Institutes of Health, the Food and Drug Administration, and the Substance Abuse and Mental Health Services Administration with coordinating studies, fast‑tracking clinical trials, and reviewing scheduling restrictions. It specifically names LSD, psilocybin, and the lesser‑known ibogaine as priority substances for investigation^[1].

Health Secretary Robert F. Kennedy Jr. said the administration’s focus on evidence‑based treatment aligns with his long‑standing call for broader therapeutic options^[2].

Some outlets reported the action as a plan rather than a completed signing. The Detroit News noted that Trump was "planning to sign" the order on Saturday, while the Washington Post described it as a directive already issued to agencies^[3]. The higher‑trust Washington Post account is used as the basis for this report.

Psychedelic research has gained momentum in recent years, with the FDA granting breakthrough‑therapy designations to psilocybin for treatment‑resistant depression and to MDMA for PTSD. Academic centers across the country are conducting controlled trials, and early results suggest significant symptom reduction for participants^[1].

Advocacy groups hailed the order as a historic step toward dismantling decades‑old barriers to study. "This could finally bring life‑changing therapies to patients who have exhausted every other option," said a spokesperson for the Psychedelic Medicine Alliance. Critics, however, said rapid expansion might outpace safety protocols and that the substances remain Schedule I drugs under federal law^[1].

If implemented, the order could prompt a reevaluation of scheduling classifications, increase federal funding for psychedelic trials, and set a precedent for other administrations to follow. It also signals a broader shift in U.S. drug policy toward therapeutic use rather than solely punitive approaches.

**What this means** The executive order positions psychedelics at the forefront of federal health research, potentially accelerating the path from lab to clinic for treatments that could address a mounting mental‑health burden. While the directive promises expanded study and possible patient access, its impact will hinge on how agencies balance scientific rigor with the urgency of unmet clinical needs.